StreetInsider.com News Articles

Form 4 Crinetics Pharmaceutical For: Mar 03 Filed by: Okey Stephanie

Wed, 04 Mar 2026 17:45:00 -0500

si-local-file:///var/storage/secattach/20260304/26113003.html

Form 4 Crinetics Pharmaceutical For: Mar 03 Filed by: Okey Stephanie

Wed, 04 Mar 2026 17:45:00 -0500

si-local-file:///var/storage/secattach/20260304/26113003.html

Form 4 Crinetics Pharmaceutical For: Mar 03 Filed by: Schilke Tobin

Wed, 04 Mar 2026 17:44:00 -0500

si-local-file:///var/storage/secattach/20260304/26112996.html

Form 4 Crinetics Pharmaceutical For: Mar 03 Filed by: Schilke Tobin

Wed, 04 Mar 2026 17:44:00 -0500

si-local-file:///var/storage/secattach/20260304/26112996.html

Form 144 Crinetics Pharmaceutical Filed by: Okey Stephanie

Tue, 03 Mar 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260303/26102770.html

Form 144 Crinetics Pharmaceutical Filed by: Okey Stephanie

Tue, 03 Mar 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260303/26102770.html

Form 8-K Crinetics Pharmaceutical For: Feb 27

Tue, 03 Mar 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260303/26101396.html

Form 8-K Crinetics Pharmaceutical For: Feb 27

Tue, 03 Mar 2026 16:11:00 -0500

si-local-file:///var/storage/secattach/20260303/26101396.html

Form 144 Crinetics Pharmaceutical Filed by: Schilke Tobin

Mon, 02 Mar 2026 10:28:00 -0500

si-local-file:///var/storage/secattach/20260302/26088876.html

Form 144 Crinetics Pharmaceutical Filed by: Schilke Tobin

Mon, 02 Mar 2026 10:28:00 -0500

si-local-file:///var/storage/secattach/20260302/26088876.html

Crinetics (CRNX) PT Lowered to $96 at Citizens on Multiple Pivotal Readouts Ahead

Mon, 02 Mar 2026 05:12:44 -0500

Citizens analyst Jonathan Wolleben lowered the price target on Crinetics (NASDAQ: CRNX) to $96.00 (from $105.00) while maintaining a Market Outperform rating.

The analyst commented, "Early launch metrics reinforce our confidence in Palsonify’s differentiated oral profile and longterm acromegaly opportunity, with physicians in our recent survey expecting 20–30% adoption —implying a $670M–$1B U.S. market versus our ~$560M peak sales estimate. CRNX also announced it received a positive opinion from the EMA’s CHMP for paltusotine, recommending marketing authorization in the EU and positioning the program for EU approval. In the pipeline, CRNX has three ongoing pivotal trials in carcinoid syndrome, pediatric and

Crinetics (CRNX) PT Lowered to $96 at Citizens on Multiple Pivotal Readouts Ahead

Mon, 02 Mar 2026 05:12:44 -0500

Citizens analyst Jonathan Wolleben lowered the price target on Crinetics (NASDAQ: CRNX) to $96.00 (from $105.00) while maintaining a Market Outperform rating.

Crinetics (CRNX) PT Lowered to $83 at Stifel

Fri, 27 Feb 2026 07:26:43 -0500

Stifel analyst Alex Thompson lowered the price target on Crinetics (NASDAQ: CRNX) to $83.00 (from $84.00) while maintaining a Buy rating.

Crinetics Pharmaceuticals (CRNX) Tops Q4 EPS by 5c

Thu, 26 Feb 2026 16:49:27 -0500

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($1.29), $0.05 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $4 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

Form S-8 Crinetics Pharmaceutical

Thu, 26 Feb 2026 16:38:00 -0500

si-local-file:///var/storage/secattach/20260226/26071934.html

Form S-8 Crinetics Pharmaceutical

Thu, 26 Feb 2026 16:38:00 -0500

si-local-file:///var/storage/secattach/20260226/26071934.html

Form 10-K Crinetics Pharmaceutical For: Dec 31

Thu, 26 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260226/26071566.html

Form 10-K Crinetics Pharmaceutical For: Dec 31

Thu, 26 Feb 2026 16:29:00 -0500

si-local-file:///var/storage/secattach/20260226/26071566.html

Form 8-K Crinetics Pharmaceutical For: Feb 26

Thu, 26 Feb 2026 16:27:00 -0500

si-local-file:///var/storage/secattach/20260226/26071502.html

Form 8-K Crinetics Pharmaceutical For: Feb 26

Thu, 26 Feb 2026 16:27:00 -0500

si-local-file:///var/storage/secattach/20260226/26071502.html

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 26 Feb 2026 16:05:00 -0500

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December

Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026

Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates

Management Hosting Conference Call at 4:30 p.m. ET Today

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Thu, 26 Feb 2026 16:05:00 -0500

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December

Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026

Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates

Management Hosting Conference Call at 4:30 p.m. ET Today

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel

Form 4 Crinetics Pharmaceutical For: Feb 23 Filed by: Struthers Richard Scott

Wed, 25 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260225/26060904.html

Form 4 Crinetics Pharmaceutical For: Feb 23 Filed by: Struthers Richard Scott

Wed, 25 Feb 2026 16:37:00 -0500

si-local-file:///var/storage/secattach/20260225/26060904.html

Form 4 Crinetics Pharmaceutical For: Feb 23 Filed by: Schilke Tobin

Wed, 25 Feb 2026 16:36:00 -0500

si-local-file:///var/storage/secattach/20260225/26060877.html